Clinical Trials Browser

Phase 1 × Brain Neoplasms × osimertinib × Clear all

NCT05120960 2024-04-17

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Phase 1 Withdrawn

Brain Neoplasms

NCT02228369 2021-01-05

BLOOM

Phase 1 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis